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Background & aims:  Under- and overnutrition are linked to adverse outcomes 
during and after childhood cancer treatment. Therefore, understanding the 
timing of weight loss and weight gain and their contributory factors is 
essential for improving outcomes. We aimed to determine in which period of 
treatment changes in nutritional status occurred and which factors contributed 
to these changes.
Methods: A prospective cohort study of 133 newly diagnosed cancer 
patients with hematological, solid, and brain malignancies was performed. 
Anthropometric data and related factors were assessed at 0, 3, 6 and 12 
months after diagnosis.
Results: Despite initial weight loss at the beginning of treatment in patients 
with hematological and solid malignancies, body mass index (BMI) and fat 
mass (FM) increased within 3 months with 0.13 SDS (P<0.001) and 0.05 
SDS (P=0.021) respectively. Increase continued during the following months 
and resulted in a doubling of the number of overnourished patients. Fat free 
mass (FFM), which was already low at diagnosis, remained low. During the 
entire study period about 17% of the patients were undernourished on the 
basis of low FFM. Tube feeding and diminished activity level were related to 
increases in BMI and %FM respectively. No relationship was found between 
energy intake or corticosteroids and increase in BMI or %FM.
Conclusions: BMI and FM increased during and after the period of intensive 
treatment, while FFM remained low. Improvement of nutritional status might 
be accomplished by increasing physical activity from the early phase of 
treatment.
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INTRODUCTION
Poor nutritional status is linked to adverse outcomes both during treatment 
of childhood cancer and during survivorship. During cancer treatment under- 
and overnutrition result in more complications, higher relapse rates, and lower 
survival rates.1,2 During survivorship, overnutrition is one of the risk factors 
for diabetes mellitus type II, hypertension, and cardiovascular diseases.3 This 
is especially a problem in cancer survivors, who run the additional risk of 
developing cardiovascular disease due to treatment with potential cardiotoxic 
chemotherapy or radiotherapy.4 Undernutrition in the general population is 
also associated with morbidity and increased all-cause mortality.5 Although 
previous studies have presented data of under- and overnutrition in childhood 
cancer patients, little is known about the timing of the onset of under- and 
overnutrition and their respective causes. It is therefore necessary to study 
the timing and the causes of changes in nutritional status in order to develop 
adequate intervention strategies. 
Nutritional status can be represented by both body size and body composition. 
Body size is measured using weight, height, and body mass index (BMI), and 
represents the general impression of the child’s growth. Body composition 
is expressed in fat mass (FM) and fat free mass (FFM), which represent the 
nutritional stores of the body.6,7 Body composition can be measured both 
by complex methods, such as air-displacement plethysmography (ADP) or 
simple methods such as bioelectrical impedance analyses (BIA).  Patients can 
be undernourished because of low BMI and/or low FFM, or overnourished 
because of high BMI and/or high FM. Both criteria are not necessarily present 
at the same time. For example, low FFM can be present in patients with normal 
BMI. In this study both body size and body composition are considered to be 
relevant.
Presumably, changes in nutritional status are caused by the malignancy or its 
treatment and continue into survivorship. Therefore, it is important to gain 
insight in the course of weight loss or weight gain and changes in body 
composition during treatment, but also to determine the factors related to 
these changes. Up till now, most studies assessing nutritional status relied on 
cross-sectional data.7 The few prospectively conducted longitudinal studies 
that did report on changes in nutritional status predominantly concerned 
patients with acute lymphoblastic leukemia (ALL) and described time intervals 
of 6 months or more, making a detailed analysis of the timing of changes 
difficult.8,9 Longitudinal studies in patients with solid and brain malignancies 
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are scarce.7 Therefore, we conducted a prospective cohort study among newly 
diagnosed cancer patients with heterogeneous malignancies and registered 
body size, body composition, and related factors during 12 months after 
diagnosis. Our research questions were: 
In which period of treatment do changes in body size and body composition 
arise?
Which factors contribute to those changes in body size and body composition?
METHODS
Participants
All children newly diagnosed with cancer, who were consecutively admitted 
to the Pediatric Oncology Department of the University Medical Center 
Groningen (UMCG) between September 2007 and December 2009 were 
asked to participate in a prospective cohort study called the Pecannut 
(Pediatric Cancer and Nutrition) study. The follow-up period was 12 months 
and ended in December 2010. Eligible patients were between 0 and 17.99 
years of age, had no prior diagnosis of cancer, had sufficient command of 
the Dutch language, and received treatment with curative intent. In total, 
150 patients were eligible for inclusion. Fifteen patients refused participation 
because they found the study too burdensome (n=13), or because a lack 
of motivation (n=2) (response rate 90%). After inclusion, 2 patients died 
before assessments, resulting in a total of 133 patients who participated in 
the study. Patients were divided in three groups: hematological, solid, and 
brain malignancies. Ethical approval was obtained from the Medical Ethics 
Committee of the UMCG, and parents and children aged ≥ 12 years gave their 
written consent.  
Procedure
Nutritional status was assessed within one week after diagnosis and at 3, 6, 
and 12 months after diagnosis by two trained observers. In addition, weight, 
height, and mid-upper arm circumference (MUAC) were measured at 3, 
6, and 9 weeks. Measurements of the patient characteristics were taken at 
diagnosis; the other related factors were assessed simultaneously with the 
measurements at diagnosis, 3 months, 6 months, and 12 months. The follow-
up measurements were taken mostly during visits to the outpatient department 
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Weight was measured using a calibrated digital scale and recorded to the 
nearest 0.1 kg (for infants to the nearest 0.01 kg). During measurements 
children only wore underwear. Height was measured using a calibrated digital 
stadiometer or an infantometer for infants, and recorded to the nearest 0.1 cm. 
MUAC was measured halfway between the tip of the acromion and olecranon 
process using a non-stretchable measuring tape SECA 212 to the nearest 0.1 
cm. Triceps skinfold thicknesses (TSF) was measured as a proxy for FM. TSF 
was measured using a Harpenden skinfold caliper in the same region and 
recorded to the nearest 0.1 mm. Both measures were performed in duplicate 
on the left arm. Data were expressed as standard deviation scores (SDS) 
calculated from Dutch reference standards.10,11 These Dutch reference standards 
were based on data of the fourth nationwide growth study performed among 
14,500 healthy children10 and a study population of 2,333 healthy children.11 
Furthermore, FFM was determined by bioelectrical impedance analyses (BIA) 
using a 50 kHz frequency BIA  (BIA 101, Akern, Italy). BIA was performed 
on the left side of the body with the patients in supine position, arms and 
legs apart, in the absence of fever, intravenous hyper-hydration, and edema. To 
calculate FFM, the equation of Goran was used.12 Subsequently, FM and %FM 
were calculated. FFM, FM, and %FM were also expressed as SDS using Dutch 
reference values.13 Undernutrition was defined as BMI<-2SDS or FFM<-2SDS, 
overnutrition as BMI>2SDS or FM>2SDS, and relevant weight loss or weight 
gain was defined as >5% change between 2 sequential measurement times.
Related factors
Patient characteristics
The patient characteristics included in this study were age, gender, diagnosis, 
initial nutritional status and body composition, and parental BMI. 
Energy intake
Energy intake was assessed using a 3-day dietary diary and total kcal was 
calculated using food calculation software (Eetmeter 2002, The Netherlands 
Nutrition Centre, The Netherlands). Percentage intake of individual energy 
requirement (using Schofield’s formula14) was calculated. In addition, it was 
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registered whether the child received oral or tube feeding. 
Treatment intensity and treatment phase
Treatment intensity was rated with the Intensity of Treatment Rating scale 
(ITR-3).15 Since only a few patients were rated either in the least intensive 
or most intensive categories, the ITR-scale was reduced to two categories: 
least/moderate intensive and very/most intensive. Furthermore, at each 
measurement time it was recorded whether a patient was still in active 
treatment or whether therapy was terminated. 
Cumulative dose of corticosteroids
Based on treatment protocol the cumulative dose of  corticosteroids (mg 
prednisone/m2) was calculated. To calculate the corresponding dose of 
dexamethasone, a conversion of 6.67 was used. Corticosteroid use after brain 
surgery was included as well.
Symptoms
The Memorial Symptom Assessment Scale (MSAS)16 was used to assess 
symptom frequency and symptom distress. Moreover, we derived two 
subscales from MSAS: a 13 item scale with feeding related symptoms and a 2 
item scale assessing nausea and vomiting (Crohnbach’s α of the 3 scales was 
within 0.76 and 0.90) (see supplement for items of both subscales).
Physical activity
The level of physical activity was assessed using the Lansky Play Performance 
Scale (PPS).17 This is a 10-point parent-rated Likert-scale that records the daily 
play activity of the child ranging from completely disabled (10) to fully active 
(100). PPS was considered as a surrogate measure for physical activity.
Data analysis and statistics
To answer the first research question, analyses were performed for the period 
of intensive treatment (0-3 months) and for the usually less intensive period of 
maintenance treatment (3-12 months). The number of patients with relevant 
weight loss or weight gain and prevalence rates of under- and overnutrition 
was calculated. Differences between patients with oral or tube feeding were 
tested with independent T-tests and Chi-square.
Multilevel analyses were performed to determine: 1) whether parameters of 
body size and body composition changed over time; 2) whether the three 
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patient groups differed with regard to body size and body composition; 
3) whether the three patient groups differed with regard to changes over 
time; and 4) which factors contributed to the changes in body size and body 
composition. In these fourth multilevel analyses, BMI SDS and %FM SDS were 
the dependent variables that represented body size and body composition 
respectively.7 Related factors were entered in the analysis using backward 
selection and were tested for main effects and interaction with time. Since 
BMI and %FM were the dependent variables in the analysis and could not be 
used as covariates as well, MUAC SDS at diagnosis was used as a substitute 
for initial body size and BMI SDS at diagnosis for body composition. As 
BMI showed a parabolic curve trajectory between 0-3 months and a linear 
trajectory between 3-12 months (Figure 2c), data of BMI were analyzed for 
two separate periods: 0-3 months, including all measurement times between 
0-3 months (time-square term was included and time was centered), and 
3-12 months, including the measurements at 3, 6, and 12 months. In order to 
build a powerful model, analyses of %FM covered the whole period of 0-12 
months. Analyses of body composition were restricted to children ≥ 4 years 
old due to the lack of valid regression equations to calculate FFM and FM 
from BIA outcomes. Multilevel analyses were performed using linear mixed 
models of SPSS 20 and likelihood ratio tests were used to determine the best 
multilevel solution. P values <0.05 were considered statistically significant.
RESULTS
Characteristics of the cohort
A total of 133 patients with hematological (39.8%), solid (33.1%), or brain 
(27.1%) malignancies were included in the study. Their median age was 8.1 
years (0.1-17.7) and 52.6% were female (Table 1). During the study period, 
18 patients left the study because they became too ill (n=3), died (n=6), 
moved (n=3), felt too much burden (n=4), or experienced lack of motivation 
(n=2) (drop-out rate 13.5%) (Figure 1). The 9 patients who left the study 
because of death or increased severity of illness, had a worse nutritional status 
compared with those who remained in the study (BMI at diagnosis = -1.38 
SDS versus BMI=0.00 SDS Mann-Whitney-U=304, P=0.023; FFM=-1.89 SDS 
versus FFM=-0.67 SDS Mann-Whitney-U=86, P=0.021).
In total, 60 (45.1%) patients received (naso) gastric tube feeding for several 
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days or weeks at any given time during the first year. These patients were 
younger (mean age 7.2 years versus 9.6 years t=2.832 P=0.005), had lower 
initial weight (mean weight-for-age (WFA)= -0.27 SDS versus WFA= 0.20 
SDS t=2.151 P=0.033), and underwent more intensive treatment (c2=24.5, 
df=2, P<0.001) than patients without tube feeding. Mean percentage energy 
intake (of individual requirements) for the whole study period was 105% 
(SD 38%). Energy intake decreased over time from 111% at the beginning of 
treatment to 96% after 12 months (estimate multilevel analysis = -1.46 (95% 
CI -2.38, -0.54), P= 0.002).
Changes in body size
0-3 months
During the first 3 months after diagnosis, relevant weight changes (>5%) were 
found in  63.7% (n=79) of the patients (Table 2). Weight loss was prevalent 
in patients with hematological and solid malignancies; whereas the majority 







missing available dataeligible patients
Fig. 1. Flow chart of follow-up. Reasons for loss to follow-up ( n ¼ 18) were: child
became too ill ( n ¼ 3), died ( n ¼ 6), moved ( n ¼ 3), felt too much burden ( n ¼ 4), or
experienced lack of motivation ( n ¼ 2).
Figur  1. F ow chart of follow-up. Reasons for loss t  follow- p ( =18) were: child became too ill (n=3), 
died ( =6), m ved (n=3), felt too much burden (n=4), or experienced lack of motivation (n=2).
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Table 1.  Characteristics of the cohort at diagnosis (n=133)
Characteristic
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(Naso) gastric tube feedinga 60 (45.1)






















a Number of patients receiving gastric tube feeding at any given time during treatment. One patient 
had gastrostomic tube feeding, all the others received nasogastric tube feeding.
b Corticosteroid use according to treatment protocol or after brain surgery.
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c. Change in BMI 
e. Change in TSF
d. Change in MUAC
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Changes in nutritional status during treatment
Figure 2.  Change in parameters of body size and body composition 0-12 months after diagnosis 
expressed in SDS. Data are presented of patients with hematological, solid, and brain malignancies. 
WFA (2a) and BMI (2c) initially decreased in patients with hematological and solid malignancies; 
whereas a rapid increase was observed in patients with brain malignancies. Within 3 months WFA and 
BMI were higher than at diagnosis in all malignancies, and the increase of BMI continued. HFA (2b) 
decreased in all patients groups, and MUAC (2d) increased. TSF (2e), %FM (2f), and FM (2g) increased 
and were higher in patients with brain malignancies compared to those with hematological and solid 
malignancies. FFM (2h) remained stable and was lower in patients with brain malignancies compared 
to patients with hematological and solid malignancies. FFM, fat free mass; FM, fat mass; HFA, height-
for-age; MUAC, mid-upper arm circumference; SDS, standard deviation score; TSF, triceps skinfold 
thickness; WFA, weight-for-age.
         hematological           solid           brain malignancies
Table 2. Weight changes >5% in different time periods.













All patients 17 (13.7) 18 (14.5) 44 (35.5) 1 (0.9) 13 (11.3) 70 (60.9)
Hematological 10 (19.6) 11 (21.6) 13 (25.5) 0 10 (20.8) 24 (50.0)
Solid 6 (14.3) 6 (14.3) 14 (33.3) 1 (2.6) 1 (2.6) 29 (74.4)
Brain 1 (3.2) 1 (3.2) 17 (54.8) 0 2 (7.1) 17 (60.7)
a In the period of 0-3 months, weight was assessed every 3 weeks, so the numbers refer to changes in 
a short period of time. Some patients lost weight in one period and gained weight in another period, 
and vice versa.
b In the period 3-12 months weight was assessed at 3, 6, and 12 months, so the numbers refer to 
changes in periods of 3 months and 6 months. Some patients lost weight in one period and gained 
weight in another period and vice versa. 
of the brain tumor patients gained weight. The number of undernourished 
patients (BMI<-2SDS) decreased from 8.3% to 4.1% at 3 months, and the 
number of overnourished patients (BMI>2SDS) increased from 4.5% till 
6.6% (Table 3).
On average, WFA increased and height-for-age (HFA) decreased (Figure 2a, 
2b, table 4). As a result BMI (Figure 2c) increased on average with 0.13 SDS 
per month. Increase in weight was also reflected in increase of MUAC (Figure 
2d, table 4). 
3-12 months
During this period of less intensive treatment, no significant increase in WFA 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and MUAC gradually increased (Table 4, figure 2c and 2d). The magnitude of 
increases in BMI and MUAC and decreases in HFA did not differ between the 
three patient groups (Supplementary table 2). Prevalence rates of overnutrition 
doubled from the time of diagnosis to 10.4% at the end of the year, and the 
prevalence of undernutrition decreased to 1.7% (Table 3).
 Despite the average increase in BMI, 12.2% (n=14) of the patients, in 
particular hematological patients, experienced >5% weight loss at any given 
time during this study period (Table 2). 
Changes in body composition
0-3 months
At diagnosis, 17.2% (n=16) of the patients were undernourished according 
to FFM<-2SDS and this number remained stable during this period (Table 
3). More than half of these patients (n=10) had normal BMI values and were 
diagnosed with brain malignancies (n=8). Based on FM>2SDS, 10.9% (n=10) 
were overnourished. However, half of the patients (n=5) with FM>2SDS had 
values of BMI<2SDS. 
Body composition changed significantly: TSF and FM increased with 0.33 
and 0.05 SDS per month respectively (Table 4, figure 2e, 2g); whereas FFM 
remained low (Figure 2h). Body composition also differed between the 
patient groups: patients with brain malignancies had higher FM and lower 
FFM compared with patients with hematological and solid malignancies 
(Supplementary table 1).
3-12 months
Changes in body composition continued during this period (Figures 2e-2h). 
However, only increase in TSF proved to be significant (Table 4). Although 
FFM in solid malignancy patients seemed to increase (Figure 2h), the 
change was not significant. The differences in body composition between the 
groups remained; higher FM and lower FFM were found in patients with 
brain malignancies (Supplementary table 2). One year after diagnosis, 18.5% 
(n=15) of the patients had FM>2SDS; these were mainly patients with ALL, 
lymphoma, and craniopharyngioma. Another 17.3% (n=14) had FFM<-
2SDS, including all malignancies. Some patients (n=4) had low FFM (FFM<-
2SDS) and high FM (FM>2SDS) at the same time. Three of these 4 patients 
were diagnosed with brain malignancies (craniopharyngioma). Mean FFM 
SDS in patients with BMI<-2 SDS was 1.09 SDS (%CI -1.68; -0.51, P=0.000) 
lower than in the overnourished patients (BMI> 2SDS).
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Factors related to changes in BMI
0-3 months
The increase in BMI during this period was related to initial nutritional 
status and tube feeding. The BMI of children with a lower nutritional status at 
diagnosis and the BMI of children who received tube feeding increased more 
(estimate of slope interaction nutritional status*time= -0.07, 95%CI -0.10; 
-0.03, P=0.000; estimate of slope interaction tube feeding*time=-0.13 per 
month, 95%CI -0.25; -0.00, P=0.047, Supplementary Table 4). Although the 
three diagnosis groups (hematological, solid, and brain malignancies) did 
not differ in the extent of increase in BMI, the trajectories of the three groups 
were different. For example, the BMI of both the hematological malignancies 
group and the solid malignancies group first decreased, only to recover within 
3 months. In contrast, the BMI of the brain malignancies group increased 
immediately after diagnosis. Furthermore, in this period older children 
had relatively lower BMI (estimate of intercept -0.04, 95%CI -0.06; -0.01, 
P=0.008), and patients with solid malignancies had relatively lower BMI than 
patients with brain malignancies (estimate of intercept -0.53, 95%CI -0.97; 
-0.10, P=.0016). 
3-12 months
No single factor appeared to be related to the increase in BMI. Hence, 
an increase in BMI between 3-12 months was not related to age, gender, 
diagnosis, BMI parents, initial nutritional status, energy intake, tube feeding, 
treatment intensity or phase, corticosteroids, symptoms, or activity.
Factors related to increase in %FM
0-12 months
The only factor related to increase in %FM was the Lansky PPS. The %FM 
of severely ill and less active children was found to increase more (estimate 
of slope interaction Lansky*time -0.001, 95%CI -0.002; -0.0002, P=0.018) 
(Supplementary table 5). Every single point decrease in PPS (scale 10-100) 
resulted in a 0.001 increase in %FM per month, indicating that a decrease of 
20 points in PPS-score contributed to an increase of 0.24 SDS in %FM over 
12 months. The increase in %FM was not related to age, gender, diagnosis, 
BMI parents, initial nutritional status, energy intake, tube feeding, treatment 
intensity or phase, corticosteroids, or symptoms. Furthermore, patients 
with brain malignancies had higher %FM than patients with hematological 
(estimate of intercept -0.74, 95%CI -1.12; -0.36, P=0.000) and solid 
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malignancies (estimate of intercept -0.89, 95%CI -1.30; -0.47, P=0.000), 
and patients with tube feeding had higher %FM than patients without tube 
feeding (estimate intercept -0.28, 95%CI -0.54; -0.03, P=0.028). 
An additional Kruskal Wallis analysis was performed to investigate the impact 
of corticosteroid doses on increase in %FM in 3 ALL risk groups. These risk 
groups, receiving different doses of corticosteroids, did not differ with regard 
to increase in %FM (H= 0.359, df=2, P=0.836).
DISCUSSION
 
This is the first study to describe the trajectories of changes in nutritional 
status during treatment of children with hematological, solid and brain 
malignancies. The greatest changes occurred within 3 months after diagnosis. 
Tube feeding and diminished activity level were identified as the significant 
contributory factors to increases in BMI and %FM respectively.
Changes in body size 
In our study, increase in BMI in patients with brain malignancies started 
immediately after diagnosis; whereas BMI in patients with hematological and 
solid malignancies initially decreased, only to increase later on. In contrast, 
other studies reported increase in BMI from the start of treatment, particularly 
in patients with ALL18,19 and craniopharyngioma.20 However, data in those 
studies were collected retrospectively, and, in general, time intervals of 6 
months or more were used. Thus, presentation of changes was less precise and 
detailed compared with the current study. In our study, for example, the BMI 
of patients with solid malignancies did not show the continuous decrease that 
has been observed elsewhere,21 but instead recovered within three months. 
Obviously, variation in nutrition policies and interventions affected the BMI 
trajectories in the different studies. Since all patient groups in the current study 
were treated according to the same nutrition policy, (nutritional assessment, a 
personal dietary advice from a dietician, and regular measurement of weight 
and height), we were in the unique position to analyze the impact of the type 
of malignancy on nutritional status.
Furthermore, we found that stagnation of growth in height contributed to 
increase in BMI. Consequently, it is important for clinicians to realize that 
in order to prevent increase in BMI during treatment weight should remain 
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stable until growth in height continues. 
Our study results indicate that despite initial weight loss in patients with 
hematological and solid malignancies, eventually all three patient groups 
were at risk for becoming overnourished. Since higher prevalence rates of 
overnutrition have also been found in childhood cancer survivors,20,22 a timely 
identification of changes in BMI during treatment is necessary to implement 
preventive measures.
Changes in body composition 
Our finding of rapid increase in FM during the first months after diagnosis is 
consistent with findings in ALL patients.9 Due to the small time intervals we 
could determine the period of rapid increase more precisely. We found that 
childhood cancer patients start gaining FM  almost immediately after diagnosis 
and during the most intensive period of treatment. There is a paucity of data 
on changes of body composition in children with solid or brain malignancies.7 
Both high6 and stable FM have been reported in solid malignancy patients.23 In 
the current study, all patient groups were found to be at risk for increase in FM. 
This increase in FM during treatment is of serious concern, particularly since 
the literature reports increased levels of FM even years after cessation of therapy 
in survivors of childhood cancer.24,25 This indicates that high FM developed 
during treatment might continue into survivorship and increase the risk of 
morbidities associated with overnutrition.
FFM was already low at diagnosis and remained low during treatment, with the 
lowest values found in patients with brain malignancies. Low FFM, at diagnosis 
and during treatment, has been reported before in ALL and solid malignancy 
patients6,9 and might be caused by weight loss or inflammation due to tumor 
activity. The abnormal body composition in patients with brain malignancies 
could be attributed to a growth hormone deficiency that was already present at 
diagnosis26 or to diminished physical activity due to motor disabilities. Some 
patients, especially patients with craniopharyngioma, had low FFM and high 
FM at the same time. Since overnutrition is more visible than undernutrition, 
the undernourishment of these patients often goes undetected.  Low FFM 
is alarming because it results in loss of muscle strength, lower tolerance for 
chemotherapy, higher risk of infections, and poorer outcomes.6 Low FFM might 
even continue after cessation of therapy as was demonstrated in survivors.25 
Therefore, further research on the onset and factors related to low FFM is 
urgently needed. 
A limitation of the current study is that only simple methods were used to 
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assess body composition. The accuracy and precision of BIA can be influenced 
by intrapersonal factors such as illness and hydration status. In addition, a 
disease specific equation for predicting FFM in childhood cancer patients 
using BIA measurements is not yet available. Triceps measurement can also be 
prone to measurement bias, especially in overnourished persons. However, 
these methods are not only fast and easy to use, but they are also acceptable 
to children. Moreover, the presentation of TSF as SDS is considered to be a 
reliable index for FM.27 By performing the measurements between courses 
of chemotherapy, in the absence of fever, hyper-hydration, and edema and by 
application of both BIA and TSF; we have tried to optimize the validity of the 
body composition assessment. Furthermore, the FM results of BIA and TSF 
were closely related and followed similar trajectories. 
Factors related to increase in BMI
Low initial nutritional status and tube feeding contributed to an increase in 
BMI. The faster increase in BMI in poorly nourished children at the time of 
diagnosis might be seen as catch-up growth. Tube feeding also contributed 
to weight gain in this particular group of children. However, it is difficult to 
draw the line between catch-up growth and overfeeding. The high percentage 
(45%) of patients receiving tube feeding combined with the high energy 
intake in the early phase of treatment not only reveals an active policy to 
prevent and treat undernutrition but also explains the rapid recovery of BMI 
after decline. Nevertheless, the continuous increase in BMI indicates that the 
average energy intake of patients exceeded their energy requirements. This 
suggests that concern about weight loss has conversely resulted in neglect of 
weight gain. 
Contrary to other studies, we did not find an association between increase in 
BMI and age, gender, or parental BMI,18,19,28 nor did we find an association 
with energy intake, treatment intensity, symptoms, or physical activity. All 
these factors were interrelated to tube feeding, making tube feeding the 
main related factor for weight gain. Considering these interrelationships, the 
need for tube feeding can be seen as a surrogate marker of children who are 
severely affected by the disease and treatment. However, despite the severity of 
their disease, BMI in these children continued to increased due to the forced 
tube feeding. Treatment with corticosteroids is often linked to increase in BMI, 
since energy intake increases during corticosteroid treatment.29,30 However, 
studies testing the impact of corticosteroids on BMI have shown contradictory 
results.19,31 In our study, an association with corticosteroid use was not found.
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Factors related to increase in %FM
Low physical activity (Lansky PPS) was found to be the main factor 
contributing to increase in %FM. This finding is congruent with research in 
healthy children and adolescents.32 Similar to increase in BMI, high energy 
intake or treatment with corticosteroids are assumed to cause increase in 
FM.6,9,23 Again, similar to the BMI results, such a relationship was not found. 
The results of the current study demonstrated that the level of activity was 
the only contributing factor to increase in %FM. Physical activity is known to 
be lower during cancer treatment,33 especially during treatment periods with 
corticosteroids.30 Due to this low level of activity, it can be concluded that 
increase in weight was due to increase in FM. 
This study is one of the very few prospective cohort studies describing the 
changes in nutritional status in patients with heterogeneous malignancies. 
Although the sample size of the separate malignancies was small, the 
longitudinal study design and low drop-out rate make the results of this study 
useful for developing nutritional strategies to improve outcomes in children 
with cancer.  
The current findings have several clinical implications. First, the fact that 
childhood cancer patients had abnormal body composition stresses the 
importance of not only assessing weight and height, but of FFM and FM as 
well. By only considering weight and height, some malnourished or obese 
children may remain unrecognized. This is particularly true for patients with 
brain malignancies. Since low FFM  is associated with poorer prognoses6, 
regular measurement of body composition, for instance using BIA, is urgently 
recommended. Second, given the low FFM and diminished physical activity, 
protein needs during treatment might be increased.34 Therefore, nutritional 
interventions aimed at treating or preventing undernutrition should meet 
these protein demands while energy intake should match patients’ energy 
requirements. In order to prevent overfeeding, nutritional status should be 
monitored more carefully. BMI growth charts could play a pivotal role here. 
Furthermore, in order to reduce FM and to increase FFM, clinicians should 
begin to focus on strategies to improve physical activity from the start of 
treatment.  
In conclusion, our findings show that significant increases in BMI and %FM 
already occurred within the first 3 months after diagnosis and eventually 
resulted in a doubling of the percentages of obese patients after 12 months. 
Nevertheless, some children did experience weight loss, and 17% were 
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malnourished according to low FFM. Improvement of nutritional status might 
be accomplished by adequate dietary intake and increased physical activity 
as to prevent energy imbalances and to improve FFM. Such measures will 
eventually contribute to better outcomes.
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 SUPPLEMENT
Items of the two subscales derived from MSAS
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Supplementary table 2. Change in SDS per month in body size and body composition in the period of 
3-12 months based on multi- level analyses. Unconditional growth models and best models (based on 
likelihood ratio test) with diagnosis as covariate are presented.
Estimate 95%CI P value Estimate 95%CI P value
Body size Unconditional growth model Conditional growth model
WFA
Intercept 0.16 -0.04, 0.37 0.118
Time 0.01 -0.004, 0.02 0.184
HFA
Intercept 0.01 -0.22, 0.25 0.905
Time -0.02 -0.03, -0.01 0.001
BMI
Intercept 0.24 0.02, 0.47 0.034
Time 0.02 0.004, 0.04 0.013
MUAC
Intercept 0.72 0.40, 1.04 0.000
Time 0.05 0.02, 0.07 0.001
Body composition
TSF
Intercept 1.43 0.89, 1.97 0000 2.34 1.38, 3.30 0.000
Time 0.07 0.02, 0.12 0.006 0.07 0.02, 0.12 0.006
Diagnosis Hematological -1.15 -2.29, -0.01 0.048
Solid -1.24 -2.46, -0.03 0.045
Brain 0
%FM
Intercept 1.27 1.02, 1.53 0.000 1.92 1.53, 2.32 0.000
Time 0.02 -0.004, 0.04 0.106 0.02 -0.003, 0.04 0.086
Diagnosis Hematological -0.80 -1.24, -0.35 0.001
Solid -0.96 -1.44, -0.49 0.000
Brain 0
FM
Intercept 0.95 0.72, 1.18 0.000 1.40 0.96, 1.84 0.000
Time 0.02 -0.02, 0.05 0.400 0.02 -0.02, 0.05 0.424
Diagnosis Hematological -0.56 -1.10, -0.01 0.046
Solid -0.65 -1.24, -0.05 0.034
Brain 0
FFM
Intercept -0.68 -0.98, -0.37 0.000 -1.49 -2.02, -0.96 0.000
Time -0.00 -0.03, 0.02 0.772 -0.00 -0.03, 0.02 0.760
Diagnosis Hematological 0.95 0.31, 1.59 0.004
Solid 1.26 0.57, 1.95 0.000
Brain 0
HFA, height-for-age; FFM, fat free mass; FM, fat mass; MUAC, mid-upper arm circumference; SDS, 
standard deviation score; TSF, triceps skinfold thickness; WFA, weight-for age. 
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Supplementary table 3. Change in SDS per month in body size and body composition in the period of 
0-12 months based on multi- level analyses. Unconditional growth models and best models (based on 
likelihood ratio test) with diagnosis as covariate are presented.
Estimate 95%CI P value Estimate 95%CI P value
Body size Unconditional growth model Conditional growth model
WFA
Intercept 0.05 -0.16, 0.25 0.655
Time 0.02 0.01, 0.03 0.001
HFA
Intercept 0.06 -0.16, 0.28 0.572
Time -0.02 -0.03, -0.02 0.000
BMI
Intercept 0.06 -0.15, 0.26 0.569
Time 0.04 0.03, 0.06 0.000
MUAC
Intercept 0.39 0.11, 0.68 0.008
Time 0.08 0.06, 0.10 0.000
Body composition
TSF
Intercept 0.97 0.57, 1.37 0.000 1.85 1.05, 2.65 0.000
Time 0.12 0.08, 0.18 0.000 0.12 0.08, 0.16 0.000
Diagnosis Hematological -1.24 -2.23, -0.25 0.015
Solid -1.04 -2.08, 0.01 0.052
Brain 0
%FM
Intercept 1.19 0.99, 1.40 0.000 1.83 1.48, 2.18 0.000
Time 0.03 0.01, 0.05 0.001 0.03 0.01, 0.05 0.001
Diagnosis Hematological -0.79 -1.21, -0.37 0.000
Solid -0.93 -1.38, -0.48 0.000
Brain 0
FM
Intercept 0.89 0.70, 1.08 0.000 1.33 0.99, 1.68 0.000
Time 0.02 0.01, 0.04 0.003 0.02 0.01, 0.04 0.002
Diagnosis Hematological -0.56 -0.99, -0.14 0.010
Solid -0.63 -1.08, -0.18 0.007
Brain 0
FFM
Intercept -0.67 -0.95, -0.39 0.000 -1.52 -2.01, -1.02 0.000
Time -0.00 -0.02, 0.01 0.622 -0.01 -0.02, 0.01 0.588
Diagnosis Hematological 1.03 0.41, 1.65 0.001
Solid 1.27 0.61, 1.92 0.000
Brain 0
 
HFA, height-for-age; FFM, fat free mass; FM, fat mass; MUAC, mid-upper arm circumference; SDS, 
standard deviation score; TSF, triceps skinfold thickness; WFA, weight-for age.
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Supplementary table 4.  Associations between daily increases in BMI SDS in the period 0-3 months using 
multilevel analysis 
Change BMI SDS 0-3 months
Estimate 95% CI P value
Intercept 0.63 0.21, 1.06 0.004
Time 0.30 0.11, 0.49 0.002
Time2 -0.10 -0.21, -0.00 0.045
Age -0.04 -0.06, -0.01 0.008
Diagnosis Hematological -0.06 -0.48, 0.35 0.766
Solid -0.53 -0.96, -0.10 0.016
Brain 0
Nutritional status Dx 0.51 0.43, 0.59 0.000
Tube feeding No 0.08 -0.12, 0.29 0.416
Yes 0
Age*time 0.00 -0.01, 0.02 0.377
Diagnosis*time Hematological 0.05 -0.13, 0.24 0.563
Solid -0.12 -0.30, 0.06 0.187
Brain 0
Nutritional statusDx*time -0.07 -0.10, -0.03 0.000
Tube feeding*time No -0.13 -0.25, -0.00 0.047
Yes 0
Diagnosis*time2 Hematological 0.20 0.07, 0.33 0.004
Solid 0.14 0.01, 0.27 0.039
Brain 0
Dependent variable: BMI SDS, time is centered. Both time and time2 are in the model and present the 
shape of a parabolic curve: the negative value of the estimate for the coefficient of time2 means that 
the parabolic curve is concave (opening down) for the reference group (in this analysis the tube fed 
patient with brain malignancy). Nutritional statusDx (=initial nutritional status) is related to increase 
in BMI: a difference of 1 SDS higher nutritional status at diagnosis results in 0.07 less increase per day. 
Tube feeding is related to increase in BMI as well: children without tube feeding increase 0.13 SDS less 
in BMI compared with children with tube feeding. Diagnosis*time2: the parabolic curves of patients 
with hematological and solid malignancies differ from patients with brain malignancies. Their parabolic 
curves are convex, meaning that BMI first decreased and subsequently increased (Figure 1a). Explained 
total variance of this model is 52.2%.
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Supplementary table 5. Associations between monthly increases in %FM SDS by using multilevel analysis 
in the period of 0-12 months
Change %FM 0-12 months
Estimate 95% CI P value
Intercept 1.99 1.45, 2.54 0.000
Time 0.14 0.06, 0.22 0.001
Nutritional status Dx 0.38 0.26, 0.49 0.000
Diagnosis Hematological -0.74 -1.12, -0.36 0.000
Solid -0.89 -1.30, -0.47 0.000
Brain 0
Tube feeding No -0.28 -0.54, -0.03 0.028
Yes 0
Lansky 0.0003 -0.006, 0.007 0.929
Lansky*time -0.001 -0.002, -0.0002 0.018
Dependent variable %FM SDS.  Lansky is associated with increase in %FM over time: with every 1 point 
decrease in Lansky, %FM increases with 0.001 per month. Explained total variance of this model is 27.2%.

